These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 16330205)

  • 121. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
    Logothetis CJ; Dexeus FH; Finn L; Sella A; Amato RJ; Ayala AG; Kilbourn RG
    J Clin Oncol; 1990 Jun; 8(6):1050-5. PubMed ID: 2189954
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
    J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
    Stadler WM; Kuzel T; Roth B; Raghavan D; Dorr FA
    J Clin Oncol; 1997 Nov; 15(11):3394-8. PubMed ID: 9363871
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
    Galsky MD; Chen GJ; Oh WK; Bellmunt J; Roth BJ; Petrioli R; Dogliotti L; Dreicer R; Sonpavde G
    Ann Oncol; 2012 Feb; 23(2):406-10. PubMed ID: 21543626
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
    Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
    Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
    Sylvester RJ; van der Meijden AP; Oosterlinck W; Witjes JA; Bouffioux C; Denis L; Newling DW; Kurth K
    Eur Urol; 2006 Mar; 49(3):466-5; discussion 475-7. PubMed ID: 16442208
    [TBL] [Abstract][Full Text] [Related]  

  • 129. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
    Galsky MD; Hahn NM; Rosenberg J; Sonpavde G; Hutson T; Oh WK; Dreicer R; Vogelzang N; Sternberg C; Bajorin DF; Bellmunt J
    Lancet Oncol; 2011 Mar; 12(3):211-4. PubMed ID: 21376284
    [No Abstract]   [Full Text] [Related]  

  • 130. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
    Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT; Jaeger D; Chan E; Harbison C; Lin CS; Tschaika M; Azrilevich A; Rosenberg JE
    Lancet Oncol; 2016 Nov; 17(11):1590-1598. PubMed ID: 27733243
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
    Sonpavde G; Galsky MD; Latini D; Chen GJ
    Clin Genitourin Cancer; 2014 Apr; 12(2):71-3. PubMed ID: 24355418
    [No Abstract]   [Full Text] [Related]  

  • 135. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group.
    Coppin CM; Gospodarowicz MK; James K; Tannock IF; Zee B; Carson J; Pater J; Sullivan LD
    J Clin Oncol; 1996 Nov; 14(11):2901-7. PubMed ID: 8918486
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
    Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
    [TBL] [Abstract][Full Text] [Related]  

  • 137. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Powles T; Eder JP; Fine GD; Braiteh FS; Loriot Y; Cruz C; Bellmunt J; Burris HA; Petrylak DP; Teng SL; Shen X; Boyd Z; Hegde PS; Chen DS; Vogelzang NJ
    Nature; 2014 Nov; 515(7528):558-62. PubMed ID: 25428503
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
    Necchi A; Joseph RW; Loriot Y; Hoffman-Censits J; Perez-Gracia JL; Petrylak DP; Derleth CL; Tayama D; Zhu Q; Ding B; Kaiser C; Rosenberg JE
    Ann Oncol; 2017 Dec; 28(12):3044-3050. PubMed ID: 28950298
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
    Calabrò F; Lorusso V; Rosati G; Manzione L; Frassineti L; Sava T; Di Paula ED; Alonso S; Sternberg CN
    Cancer; 2009 Jun; 115(12):2652-9. PubMed ID: 19396817
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
    Fradet Y; Bellmunt J; Vaughn DJ; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Nam K; Frenkl TL; Perini RF; de Wit R; Bajorin DF
    Ann Oncol; 2019 Jun; 30(6):970-976. PubMed ID: 31050707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.